Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | RAD52 | P43351 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | APAF1 | O14727 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 6/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 6/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 0.36 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2772650 | 0.88 | RAD52 (0.43) | KDM4ERAD52HTTLMNAKMT2A | |
| SCHEMBL2772283 | 0.87 | KDM4E (0.47) | KDM4ERAD52HTTLMNAKMT2A | |
| SCHEMBL2774380 | 0.85 | RAD52 (0.47) | KDM4ERAD52HTTLMNAKMT2A | |
| SCHEMBL2773742 | 0.85 | SMN1; SMN2 (0.41) | KDM4ERAD52HTTLMNAKMT2A | |
| SCHEMBL2772141 | 0.85 | LMNA (0.41) | KDM4ERAD52HTTLMNAKMT2A | |
| SCHEMBL2774444 | 0.85 | KDM4E (0.41) | KDM4ERAD52HTTLMNAKMT2A | |
| SCHEMBL2774140 | 0.85 | RAD52 (0.45) | KDM4ERAD52HTTLMNAKMT2A | |
| SCHEMBL2773495 | 0.83 | LMNA (0.48) | KDM4ERAD52HTTLMNAKMT2A | |
| SCHEMBL2774351 | 0.83 | KDM4E (0.47) | KDM4ERAD52HTTLMNAKMT2A | |
| SCHEMBL2775656 | 0.83 | RAD52 (0.46) | KDM4ERAD52HTTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-06-03 | — | — | US | claimed |
| EP-2152675-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-02-17 | — | — | EP | claimed |
| WO-2008152223-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2008-12-18 | — | — | WO | claimed |
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2152675-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008152223-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | CDC25A, CDC25B, CDC25C | KDM4E 2170/4885RAD52 325/4885HTT 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.